<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01970033</url>
  </required_header>
  <id_info>
    <org_study_id>HR-SP2086-301</org_study_id>
    <nct_id>NCT01970033</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of SP2086 as Monotherapy in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Multicenter Randomized, Double-blind, Placebo Controlled ,Parallel Group ,Phase III Study to Access the Efficacy and Safety of SP2086 Treated Type 2 Diabetes Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SP2086 is a new dipeptidy1 peptidase(DPP)-4 inhibitors. This study aims to evaluate the
      efficacy and safety of SP2086 as monotherapy in patients with Type 2 Diabetes Mellitus in
      Metformin monotherapy Who Have Inadequate Glycemic Control treated with diet and exercise for
      3 months
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in HbA1c (Hemoglobin A1C) at Week24</measure>
    <time_frame>baseline, week 24</time_frame>
    <description>A1C is measured as a percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in fasting plasma glucose (FPG) at Week 24</measure>
    <time_frame>Weeks 0-24</time_frame>
    <description>Change from baseline at Week 24 is defined as Week 24 FPG minus Week 0 FPG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 2-hour Post-meal Glucose (2-hr PMG) at Week 24</measure>
    <time_frame>Weeks 0-24</time_frame>
    <description>Change from baseline at Week 24 is defined as Week 24 2-hr PMG minus Week 0 2-hr PMG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Less Than (&lt;) 6.5% or &lt;7% HbA1c Levels</measure>
    <time_frame>week24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in A1C at Week 52</measure>
    <time_frame>week 52</time_frame>
    <description>A1C is measured as a percent. Thus, this change from baseline reflects the Week 52 A1C percent minus the Week 0 A1C percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FPG at Week 52</measure>
    <time_frame>week 52</time_frame>
    <description>Change from baseline at Week 52 is defined as Week 104 FPG minus Week 0 FPG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in lipid at Week 4、8、12、24、38、52</measure>
    <time_frame>Week 4、8、12、24、38、52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Week 4,8,12、24、38、52</measure>
    <time_frame>Week 4、8、12、24、38、52</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SP2086 50 mg b.i.d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SP2086 100 mg q.d.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Run in period ：oral tablets of Placebo twice daily for 2 weeks
Phase A : oral tablets of Placebo twice daily for 24 weeks
Phase B : SP2086 50 mg b.i.d or SP2086 100 mg q.d. for 28 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SP2086 50 mg b.i.d.</intervention_name>
    <description>Run-in period: placebo twice daily for 2 weeks
Phase A:SP2086 50 mg b.i.d for 24 weeks
Phase B:SP2086 50 mg b.i.d for 28 weeks</description>
    <arm_group_label>SP2086 50 mg b.i.d</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SP2086 100 mg q.d.</intervention_name>
    <description>Run-in period:placebo twice daily for 2 weeks
Phase A: SP2086 100 mg q.d. for 24 weeks
Phase B: SP2086 100 mg q.d. for 28 weeks</description>
    <arm_group_label>SP2086 100 mg q.d.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with type 2 diabetes mellitus

          -  Patients have treated with diet/exercise at least 3 months

          -  7.5% ≤HbA1C ≤11.0% at screening,7.0% ≤HbA1C ≤10.5% after run-in

        Exclusion Criteria:

          -  Patient has history of type 1 diabetes mellitus

          -  Patient has history of ketoacidosis

          -  Patient has history of severe unconscious hypoglycemosis

          -  Patient has history of acute and chronic pancreatitis or pancreatic injury that may
             lead to high risk of pancreatitis

          -  Patient has history of decompensated heart failure (NYHA class III and IV), unstable
             angina, stroke or transient ischemic attack, myocardial infarction, persistence and
             clinical

          -  Patient has history of a history of hypertension, and after antihypertensive
             treatment, systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg

          -  Patient has severe liver or kidney disease,alanine aminotransferase &gt;2×UNL, Aspartate
             Aminotransferase &gt;2×upper normal limit(UNL)；total bilirubin &gt;2×UNL； creatinine&gt;1.5
             mg/dL (Male,132.6μmol/L) ，&gt;1.4 mg/dL(Female，123.8μmol/L)

          -  Patient has severe chronic gastrointestinal disease or therapy that may affect drug
             absorption, such as gastrointestinal surgery

          -  Patient has severe haematological diseases or other diseases leading to hemolyze and
             red blood cell unstable (malaria、haemolytic anaemia eg. )

          -  Patient has other endocrine diseases, for example
             hyperthyroidism、hypothyroidism、hypercortisolism、multiple endocrine neoplasia and so on

          -  Patient has history of malignancy

          -  Patient has history of alcohol or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changyu Pan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Changyu Pan, M.D.</last_name>
    <phone>86 10 66887329</phone>
    <email>panchy301@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Huaqiong Shen, P.H.D</last_name>
    <phone>86 21 68868570</phone>
    <phone_ext>827</phone_ext>
    <email>shenhuaqiong@hrs.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changyu Pan, M.D.</last_name>
      <email>panchy301@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Changyu Pan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2013</study_first_submitted>
  <study_first_submitted_qc>October 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2013</study_first_posted>
  <last_update_submitted>October 22, 2013</last_update_submitted>
  <last_update_submitted_qc>October 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SP2086</keyword>
  <keyword>Phase III</keyword>
  <keyword>Monotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

